# Lunsekimig PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lunsekimig

> The next catalyst for lunsekimig, sponsored by Sanofi (SNY), is its topline data readout, Jun to Sep 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | lunsekimig |
| Codes | SAR443765 |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | [Chronic Obstructive Pulmonary Disease](https://sec-api.dev/indications/chronic-obstructive-pulmonary-disease), [Chronic Rhinosinusitis With Nasal Polyps](https://sec-api.dev/indications/chronic-rhinosinusitis-with-nasal-polyps), [Dermatitis Atopic](https://sec-api.dev/indications/dermatitis-atopic), [Asthma](https://sec-api.dev/indications/asthma) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### January 29, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Chronic Rhinosinusitis With Nasal Polyps.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06454240 (A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-29 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06454240

### February 12, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Dermatitis Atopic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06790121 (A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-12 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06790121

### February 23, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06102005 (Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06102005

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06676319 (Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06676319

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06676319 (Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-21 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06676319

### Feb to May 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Chronic Rhinosinusitis With Nasal Polyps.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06914908 (Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-02-22 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06914908

### February 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Chronic Rhinosinusitis With Nasal Polyps.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06914908 (Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-02-22 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06914908

### Nov 2029 to Feb 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Obstructive Pulmonary Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07190209 (Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11-27 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07190209

### Nov 2029 to Feb 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Obstructive Pulmonary Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07190222 (Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11-27 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07190222

### November 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Obstructive Pulmonary Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07190209 (Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11-27 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07190209

### November 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Obstructive Pulmonary Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07190222 (Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11-27 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07190222

## Same indication

- [Amlitelimab](https://sec-api.dev/pdufa/amlitelimab) (SNY)
- [Aro-rage](https://sec-api.dev/pdufa/aro-rage) (ARWR)
- [Atuliflapon](https://sec-api.dev/pdufa/atuliflapon) (AZN)
- [AZD4604](https://sec-api.dev/pdufa/azd4604) (AZN)
- [AZD8630](https://sec-api.dev/pdufa/azd8630) (AZN)
- [Bda mdi](https://sec-api.dev/pdufa/bda-mdi) (AZN)
- [Bda mdi hfo 160/180 μg](https://sec-api.dev/pdufa/bda-mdi-hfo-160) (AZN)
- [Fasenra (benralizumab)](https://sec-api.dev/pdufa/benralizumab) (AZN)
- [Bff mdi](https://sec-api.dev/pdufa/bff-mdi) (AZN)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Budesonide/albuterol metered dose inhaler, mdi](https://sec-api.dev/pdufa/budesonide-albuterol-metered-dose-inhaler-mdi) (AZN)
- [Depemokimab](https://sec-api.dev/pdufa/depemokimab) (GSK)
- [Dupilumab coformulated with berahyaluronidase alfa](https://sec-api.dev/pdufa/dupilumab-coformulated-with-berahyaluronidase-alfa) (SNY)
- [Ff/umec/vi](https://sec-api.dev/pdufa/ff-umec-vi) (GSK)
- [Fp/abs](https://sec-api.dev/pdufa/fp-abs) (TEVA)
- [Qbrexza (glycopyrronium tosylate)](https://sec-api.dev/pdufa/glycopyrronium) (DERM)
- [Gp mdi](https://sec-api.dev/pdufa/gp-mdi) (AZN)
- [Gsk3511294 (depemokimab)](https://sec-api.dev/pdufa/gsk3511294-depemokimab) (GSK)
- [GSK5784283](https://sec-api.dev/pdufa/gsk5784283) (GSK)
- [HFA-152A](https://sec-api.dev/pdufa/hfa-152a) (GSK)
- [Intervention: as mdi](https://sec-api.dev/pdufa/intervention-as-mdi) (AZN)
- [Itepekimab (sar440340)](https://sec-api.dev/pdufa/itepekimab-sar440340) (SNY)
- [JNJ-95597528](https://sec-api.dev/pdufa/jnj-95597528) (JNJ)
- [Londamocitinib](https://sec-api.dev/pdufa/londamocitinib) (AZN)
- [Nucala (mepolizumab)](https://sec-api.dev/pdufa/mepolizumab) (GSK)
- [Pf-07275315 dose 1](https://sec-api.dev/pdufa/pf-07275315) (PFE)
- [QMF149](https://sec-api.dev/pdufa/qmf149) (NVS)
- [QVM149](https://sec-api.dev/pdufa/qvm149) (NVS)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)
- [Salbutamol hfa-134a](https://sec-api.dev/pdufa/salbutamol-hfa-134a) (GSK)
- [TEV-56248](https://sec-api.dev/pdufa/tev-56248) (TEVA)
- [TEZSPIRE® (tezepelumab)](https://sec-api.dev/pdufa/tezepelumab) (AZN)
- [Tilrekimig](https://sec-api.dev/pdufa/tilrekimig) (PFE)
- [Tozorakimab](https://sec-api.dev/pdufa/tozorakimab) (AZN)
- [Tozorakimab dose regimen 1](https://sec-api.dev/pdufa/tozorakimab-dose-regimen-1) (AZN)
- [Treatment a : budesonide, glycopyrronium, and formoterol fumarate](https://sec-api.dev/pdufa/treatment-a-budesonide-glycopyrronium-and-formoterol) (AZN)
- [Verekitug](https://sec-api.dev/pdufa/verekitug) (UPB)
- [Verekitug (upb-101)](https://sec-api.dev/pdufa/verekitug-upb-101) (UPB)
- [WIN378](https://sec-api.dev/pdufa/win378) (WWB)

Calendar months: [June 2027](https://sec-api.dev/fda-calendar/2027-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lunsekimig.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Lunsekimig PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lunsekimig

```bibtex
@misc{secapidev_pdufa_lunsekimig_20261116,
  title        = {Lunsekimig PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lunsekimig}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lunsekimig_20261116","title":"Lunsekimig PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lunsekimig","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
